Skip to main content

Table 1 Baseline characteristics by study arm

From: Somatic and sociodemographic predictors of depression outcome among depressed patients with coronary artery disease - a secondary analysis of the SPIRR-CAD study

 

Intervention group (n = 285)

Control group (n = 285)

Characteristics

n/total valid n

%

n/total valid n

%

Demographics

 Age, mean ± SD (total valid n), y

59.1 ± 9.8 (285)

 

59.3 ± 9.3 (285)

 

 Female sex

61/285

(21.4)

59/285

(20.7)

 Married

170/268

(63.4)

185/271

(68.3)

Socioeconomic status

 Low

117/285

(45.0)

123/261

(47.1)

 Medium

84/285

(32.3)

71/261

(27.2)

 High

59/285

(22.7)

67/261

(25.7)

Baseline medical data

 Hypertension

252/281

(89.7)

245/280

(87.5)

 Hyperlipidemia

236/273

(86.4)

240/270

(88.9)

 Diabetes mellitus

69/275

(25.1)

70/279

(25.1)

 TSH, mean ± SD (total valid n), mU/l

1.6 ± 1.1 (187)

 

1.5 ± 1.2 (175)

 

 BMI, mean ± SD (total valid n), kg/m2

28.5 ± 5.0 (280)

 

28.4 ± 4.8 (275)

 

 Smokers

90/282

(31.9)

97/284

(34.2)

 Physically active

140/285

(49.1)

120/285

(42.1)

 Previous myocardial infarction

139/271

(51.3)

161/273

(59.0)

 Previous CABG

53/283

(18.7)

45/282

(16.0)

 Recent acute myocardial infarction

93/285

(32.6)

94/285

(33.0)

 Recent coronary intervention (PCI, CABG)

204/285

(71.6)

206/285

(72.3)

 NYHA class I-II

240/285

(84.2)

242/285

(84.9)

 NYHA class III

45/285

(15.8)

43/285

(15.1)

 Charlson Comorbidity Index, median (IQR)

2

(1/3)

2

(1/3)

 SF-36, mean ± SD (total valid n),

59.0 ± 24.9 (268)

 

55.6 ± 26.4 (271)

 

Baseline medication

 Thyroid substitution

34/285

(11.9)

30/285

(10.5)

 Continued intake (until T3)

11/285

(3.9)

14/285

(4.9)

 Uric acid lowering agents

24/285

(8.4)

24/285

(8.4)

 Antibiotics

2/285

(0.7)

2/285

(0.7)

 ACE inhibitors

187/285

(65.6)

193/285

(67.7)

 Aspirin

257/285

(90.2)

262/285

(91.9)

 β-Blockers

246/285

(86.3)

257/285

(90.2)

 Statins

256/285

(89.8)

265/285

(93.0)

 Antidepressant medication

33/285

(11.6)

36/285

(12.6)

HADS-D depression subscale, mean ± SD (total valid n)

 Baseline

10.4 ± 2.5 (284)

 

10.4 ± 2.5 (284)

 

 After 18 months (T3)

8.7 ± 4.1 (284)

 

8.9 ± 3.9 (285)

 
  1. TSH Thyroid-stimulating hormone, BMI body mass index, CABG coronary artery bypass graft surgery, PCI percutaneous coronary intervention, NYHA New York Heart Association, IQR interquartile range, SF-36 Short Form Health Survey – physical functioning-36-item, ACE Angiotensin-converting enzyme, HADS-D Hospital Anxiety and Depression Scale - German version (depression subscale)
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us